ACADIA Pharmaceuticals - ACAD Stock Forecast, Price & News

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 8 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ACAD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACAD, but not buy additional shares or sell existing shares.
View ACAD analyst ratings or view top-rated stocks.

18 analysts have issued 1-year price targets for ACADIA Pharmaceuticals' shares. Their ACAD share price forecasts range from $10.00 to $35.00. On average, they predict the company's stock price to reach $22.29 in the next twelve months. This suggests a possible upside of 38.1% from the stock's current price.
View analysts price targets for ACAD or view top-rated stocks among Wall Street analysts.

ACADIA Pharmaceuticals' stock was trading at $23.34 at the start of the year. Since then, ACAD shares have decreased by 30.8% and is now trading at $16.14.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our ACAD earnings forecast.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its earnings results on Monday, August, 8th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.04. The biopharmaceutical company had revenue of $134.56 million for the quarter, compared to analysts' expectations of $130.06 million. ACADIA Pharmaceuticals had a negative net margin of 39.93% and a negative trailing twelve-month return on equity of 41.18%. The firm's revenue was up 16.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.27) earnings per share.

ACADIA Pharmaceuticals updated its FY 2022 earnings guidance on Tuesday, September, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $510.00 million-$540.00 million, compared to the consensus revenue estimate of $531.12 million.

8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACAD stock can currently be purchased for approximately $16.14.

ACADIA Pharmaceuticals (NASDAQ:ACAD) has a market capitalization of $2.61 billion and generates $484.14 million in revenue each year. The biopharmaceutical company earns $-167,870,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis.

The company employs 514 workers across the globe.

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.acadia-pharm.com. The biopharmaceutical company can be reached via phone at (858) 558-2871, via email at ir@acadia-pharm.com, or via fax at 858-558-2872.